UBT251
UBT251 Injection Phase II Clinical Study (CKD)
The United Bio-Technology (Hengqin) Co · Phase 2 · Recruiting · Enrollment 180
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 2.0 mg group | n/r | n/r | n/r | n/r |
| 4.0 mg group | n/r | n/r | n/r | n/r |
| 6.0 mg group | n/r | n/r | n/r | n/r |
Not shown
- 2.0 mg group: endpoint not reported
- 4.0 mg group: endpoint not reported
- 6.0 mg group: endpoint not reported